Chemistry:Apronal
Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926[1] by Hoffmann-La Roche. Though it is not a barbiturate, apronal is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring).[2] In accordance, it is similar in action to the barbiturates, although considerably milder in comparison (formerly used as a daytime sedative at doses of 1 to 2 grams every 3 to 4 hours).[2] Upon the finding that it caused patients to develop thrombocytopenic purpura, apronal was withdrawn from clinical use.[3]
Medicines with apronal are no longer used except in Japan and South Korea.[3][4] Australian Therapeutic Goods Administration issued a safety alert in May 2023 which prohibits the sale, supply and use of Japanese EVE-branded products in Australia[5] due to its dangerous side effects.
See also
- Bromoureide
- Japanese: アリルイソプロピルアセチル尿素
References
- ↑ "Verfahren zur Darstellung von Ureiden der Dialkylessigsaeuren" DE patent 459903, issued 15 May 1928, assigned to Hoffmann-La Roche
- ↑ 2.0 2.1 Roche Review .... Hoffman-La Roche, and Roche-organon. 1938. p. 164. https://books.google.com/books?id=D20zAQAAIAAJ.
- ↑ 3.0 3.1 Fairbrother's Textbook of Bacteriology. Elsevier Science. 20 May 2014. pp. 152–. ISBN 978-1-4831-4178-7. https://books.google.com/books?id=QnDiBQAAQBAJ&pg=PA152.
- ↑ "약학정보원". https://www.health.kr/searchDrug/result_drug.asp?drug_cd=2009071505656.
- ↑ "EVE Apronal tablets". Therapeutic Goods Administration (TGA). https://www.tga.gov.au/news/safety-alerts/eve-allylisopropylacetylurea-tablets.
 |  |
